3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
19
Phase 1
8
Phase 1/2
4
Phase NA
2
Phase 3
2
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Neoplasm Metastasis
1
Interventions
Cisplatin
22
Fluorouracil
21
Radiotherapy
18
Gemcitabine
17
Docetaxel
16
Oxaliplatin
15
Paclitaxel
14
Carboplatin
13
Capecitabine
13
Bevacizumab
13
Leucovorin
11
Cyclophosphamide
11
Irinotecan
10
Drug Therapy
10
Cytarabine
9
Saline Solution
7
Magnetic Resonance Spectroscopy
7
Letrozole
7
Dexamethasone
7
Rituximab
6
Nivolumab
6
Methotrexate
6
Exercise
6
Etoposide
6
Electroporation
6
Doxorubicin
6
pembrolizumab
5
Pemetrexed
5
Metformin
5
Melphalan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Completed
×
abiraterone
×
Clear all
NCT03295565
2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3
Completed
100 enrolled